Lenalidomide, which is known to induce in T cells the secretion of IL-2, IFN-γ, and TNF-α, showed promising results in several pre-clinical cancer models in combination with mAbs inducing in NK cells antibody-dependent cytotoxicity (ADCC) (e.g., anti-CD20 in lymphoma and chronic lymphocytic leukemia) [79,80,81] and in clinical trials both in adult and children, with an increased number of cytotoxic NK cells [82,83]. The gene discussed is TNF; the disease is cancer.